ALK Shuffles Leadership as New EVP Takes Helm of Strategy
Event summary
- Tina Abild Olesen appointed Executive Vice President for Corporate, Portfolio and Product Strategy at ALK, effective October 1, 2026.
- Succeeds Jacob Glenting, who moved to Executive Vice President for Research & Development on September 1, 2026.
- Olesen brings 30 years of commercial leadership experience from GlaxoSmithKline and Novo Nordisk.
- Previously led Novo Nordisk’s Global Commercial Diabetes Franchise.
The big picture
ALK’s appointment of Tina Abild Olesen reflects a strategic realignment aimed at strengthening its corporate and therapeutic area strategies. With a background in commercial leadership from GlaxoSmithKline and Novo Nordisk, Olesen’s experience in diverse markets and major product launches positions her to drive ALK’s global commercial execution. This move comes as the company seeks to expand its reach in the allergy and allergic asthma treatment space, competing with other pharmaceutical giants.
What we're watching
- Strategic Execution
- How Olesen’s experience in large-scale transformations will shape ALK’s therapeutic area strategy.
- Portfolio Prioritization
- Whether ALK can sustain robust global commercial execution under new leadership.
- Market Expansion
- The pace at which ALK can reach more people with allergy across multiple therapy areas.
Related topics